{"id":"ag120","safety":{"commonSideEffects":[{"rate":"34%","effect":"Fatigue"},{"rate":"24%","effect":"Nausea"},{"rate":"21%","effect":"Diarrhea"}]},"_chembl":{"chemblId":"CHEMBL4282663","moleculeType":"Small molecule","molecularWeight":"597.00"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"AG-120 is an inhibitor of the mutant isocitrate dehydrogenase 1 (IDH1) enzyme, which is a key driver of cancer cell growth and survival in certain types of cancer.","oneSentence":"Inhibits mutant IDH1 enzyme","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T06:30:02.298Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute myeloid leukemia (AML) with isocitrate dehydrogenase 1 (IDH1) mutation"}]},"trialDetails":[{"nctId":"NCT04195555","phase":"PHASE2","title":"Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial)","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-07-20","conditions":"Recurrent Ependymoma, Recurrent Ewing Sarcoma, Recurrent Hepatoblastoma","enrollment":3},{"nctId":"NCT05756777","phase":"PHASE1","title":"A Study of Gilteritinib in Combination With Ivosidenib or Enasidenib in People With Acute Myeloid Leukemia (AML)","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2023-06-26","conditions":"Acute Myeloid Leukemia (AML)","enrollment":18},{"nctId":"NCT07260175","phase":"PHASE2","title":"Phase II Study Evaluating Ivosidenib Maintenance After SOC Adjuvant Chemotherapy in Curative mIDH1 Cholangiocarcinoma","status":"RECRUITING","sponsor":"Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest","startDate":"2025-11-18","conditions":"Cholangiocarcinoma, IDH Mutation","enrollment":40},{"nctId":"NCT03471260","phase":"PHASE1, PHASE2","title":"Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2018-03-19","conditions":"Acute Myeloid Leukemia, Hematopoietic and Lymphoid System Neoplasm, Myelodysplastic Syndrome","enrollment":96},{"nctId":"NCT07463768","phase":"PHASE2","title":"Study Evaluating the Efficacy and Safety of the Addition of Ivosidenib to Oral Azacitidine (Onureg®) in Patients Over 55 With Acute Myeloid Leukemia (AML) and IDH1 Mutation, in Complete Remission After Intensive Chemotherapy.","status":"NOT_YET_RECRUITING","sponsor":"French Innovative Leukemia Organisation","startDate":"2026-09","conditions":"Acute Myeloid Leukemia","enrollment":60},{"nctId":"NCT06713837","phase":"PHASE3","title":"IMPACT-AML: A Randomized Pragmatic Clinical Trial for Relapsed or Refractory Acute Myeloid Leukemia.","status":"RECRUITING","sponsor":"Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS","startDate":"2025-02-27","conditions":"Acute Myeloid Leukemia, Relapse/Recurrence","enrollment":339},{"nctId":"NCT06707493","phase":"PHASE2","title":"Ivosidenib as Post-HSCT Maintenance for AML","status":"RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2026-01-16","conditions":"IDH1 Mutation, Acute Myeloid Leukemia (AML), Hematopoietic Stem Cell Transplant (HSCT)","enrollment":75},{"nctId":"NCT07392242","phase":"PHASE2","title":"A Study of the Combination of Ivosidenib, Azacitidine, and Venetoclax Followed by Ivosidenib Alone in People With Acute Myeloid Leukemia","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2026-01-27","conditions":"Acute Myeloid Leukemia","enrollment":45},{"nctId":"NCT02677922","phase":"PHASE1, PHASE2","title":"A Study to Assess the Safety and Efficacy of Two Combinations of Isocitrate Dehydrogenase (IDH) Mutant Targeted Therapies Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) Harboring IDH Mutations Who Are Not Candidates to Receive Intensive Induction Chemotherapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Celgene","startDate":"2016-06-03","conditions":"Leukemia, Myeloid, Acute","enrollment":130},{"nctId":"NCT05876754","phase":"PHASE3","title":"An Early Access Study of Ivosidenib in Patients With a Pretreated Locally Advanced or Metastatic Cholangiocarcinoma","status":"RECRUITING","sponsor":"Servier Affaires Médicales","startDate":"2023-05-03","conditions":"Cholangiocarcinoma","enrollment":220},{"nctId":"NCT07006688","phase":"PHASE1","title":"A Study of an IDH1m Inhibitor in Participants With IDH1-Mutated Malignancies and Hepatic or Renal Impairment","status":"RECRUITING","sponsor":"Servier Bio-Innovation LLC","startDate":"2026-01-14","conditions":"IDH1-Mutated Malignancies","enrollment":30},{"nctId":"NCT02073994","phase":"PHASE1","title":"Study of Orally Administered AG-120 in Subjects With Advanced Solid Tumors, Including Glioma, With an IDH1 Mutation","status":"COMPLETED","sponsor":"Institut de Recherches Internationales Servier","startDate":"2014-03-01","conditions":"Cholangiocarcinoma, Chondrosarcoma, Glioma","enrollment":174},{"nctId":"NCT03343197","phase":"PHASE1","title":"Study of AG-120 and AG-881 in Subjects With Low Grade Glioma","status":"COMPLETED","sponsor":"Institut de Recherches Internationales Servier","startDate":"2018-03-20","conditions":"Glioma","enrollment":49},{"nctId":"NCT05921760","phase":"PHASE1, PHASE2","title":"Ivosidenib, Nivolumab, and Ipilimumab Combination in Previously Treated Subjects With Nonresectable or Metastatic IDH1 Mutant Cholangiocarcinoma","status":"TERMINATED","sponsor":"Servier Bio-Innovation LLC","startDate":"2023-10-23","conditions":"IDH1-mutant Cholangiocarcinoma","enrollment":7},{"nctId":"NCT06611839","phase":"PHASE1, PHASE2","title":"Venetoclax in Combination With Ivosidenib and Azacitidine for Newly Diagnosed IDH1-Mutated AML","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2025-10-17","conditions":"AML, IDH1 Mutation, Treatment","enrollment":29},{"nctId":"NCT06465953","phase":"PHASE3","title":"Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation","status":"RECRUITING","sponsor":"Institut de Recherches Internationales Servier","startDate":"2024-12-03","conditions":"Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS), Myelodysplastic Syndromes (MDS)","enrollment":48},{"nctId":"NCT06181734","phase":"","title":"Ivosidenib (TIBSOVO®) Combined With Azacitidine According to Current SmPC","status":"COMPLETED","sponsor":"iOMEDICO AG","startDate":"2023-12-20","conditions":"Acute Myeloid Leukemia (AML)","enrollment":8},{"nctId":"NCT03155620","phase":"PHASE2","title":"Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2017-07-31","conditions":"Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Non-Hodgkin Lymphoma, Ann Arbor Stage IV Non-Hodgkin Lymphoma","enrollment":1376},{"nctId":"NCT06127407","phase":"PHASE3","title":"Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment Regimen","status":"RECRUITING","sponsor":"Servier Bio-Innovation LLC","startDate":"2024-07-09","conditions":"Locally Advanced or Metastatic Conventional Chondrosarcoma With an IDH1 Mutation, Untreated or Previously Treated With 1 Systemic Treatment Regimen","enrollment":136},{"nctId":"NCT06648473","phase":"NA","title":"Repeatability of Magnetic Resonance Imaging in Patients With IDH1 Mutant Glioma on Ivosidenib","status":"WITHDRAWN","sponsor":"Duke University","startDate":"2026-01-01","conditions":"Low Grade Glioma of Brain","enrollment":""},{"nctId":"NCT05010772","phase":"PHASE1","title":"Decitabine Alone or in Combination With Venetoclax, Gilteritinib, Enasidenib, or Ivosidenib as Maintenance Therapy for the Treatment of Acute Myeloid Leukemia in Remission","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-10-25","conditions":"Acute Myeloid Leukemia","enrollment":125},{"nctId":"NCT06501625","phase":"PHASE1, PHASE2","title":"Ivosidenib Plus Durvalumab and Gemcitabine/Cisplatin as First-Line Therapy in Participants With Locally Advanced or Metastatic Cholangiocarcinoma With an IDH1 Mutation","status":"RECRUITING","sponsor":"Institut de Recherches Internationales Servier","startDate":"2024-12-16","conditions":"Locally Advanced, Unresectable or Metastatic Cholangiocarcinoma With an IDH1 Mutation","enrollment":52},{"nctId":"NCT03013998","phase":"PHASE1, PHASE2","title":"Study of Biomarker-Based Treatment of Acute Myeloid Leukemia","status":"RECRUITING","sponsor":"Beat AML, LLC","startDate":"2016-11","conditions":"Previously Untreated Relapsed Refractory Acute Myeloid Leukemia","enrollment":3000},{"nctId":"NCT07282262","phase":"PHASE2","title":"An Exploratory Study on the Use of Ivosidenib for the Precise Treatment of Advanced Biliary Tract Malignancies With IDH1 Mutations in the Later Line of Therapy.","status":"RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2024-05-01","conditions":"Biliary Tract Cancer","enrollment":300},{"nctId":"NCT06081829","phase":"PHASE2","title":"A Phase 2 Study of Ivosidenib in Previously Treated Japanese Subjects With Nonresectable or Metastatic Cholangiocarcinoma With an IDH1 Mutation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Servier","startDate":"2023-10-10","conditions":"Cholangiocarcinoma Non-resectable, Cholangiocarcinoma Metastatic","enrollment":12},{"nctId":"NCT06607302","phase":"","title":"Ivosidenib in Locally Advanced or Metastatic Cholangiocarcinoma With IDH1 R132 Mutation After at Least One Prior Systemic Treatment - an Observational Study","status":"RECRUITING","sponsor":"iOMEDICO AG","startDate":"2024-10-08","conditions":"Cholangiocarcinoma","enrollment":100},{"nctId":"NCT06377579","phase":"","title":"OBServatory of Compassionate Use of IVOsidenib in France for Patients With Acute Myeloid Leukemia","status":"RECRUITING","sponsor":"French Innovative Leukemia Organisation","startDate":"2024-07-31","conditions":"AML, Adult","enrollment":250},{"nctId":"NCT04493164","phase":"PHASE2","title":"CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2020-12-30","conditions":"Acute Myeloid Leukemia With Gene Mutations, Myelodysplastic Syndrome, Myeloproliferative Neoplasm","enrollment":30},{"nctId":"NCT03498521","phase":"PHASE2","title":"A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2018-07-10","conditions":"Cancer of Unknown Primary Site","enrollment":529},{"nctId":"NCT03173248","phase":"PHASE3","title":"Study of AG-120 (Ivosidenib) vs. Placebo in Combination With Azacitidine in Participants With Previously Untreated Acute Myeloid Leukemia With an IDH1 Mutation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Institut de Recherches Internationales Servier","startDate":"2017-06-26","conditions":"Newly Diagnosed Acute Myeloid Leukemia (AML), Untreated AML, AML Arising From Myelodysplastic Syndrome (MDS)","enrollment":146},{"nctId":"NCT04774393","phase":"PHASE1, PHASE2","title":"Decitabine/Cedazuridine and Venetoclax in Combination With Ivosidenib or Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-05-24","conditions":"Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia","enrollment":84},{"nctId":"NCT06291987","phase":"PHASE1","title":"Ivosidenib and Ruxolitinib in Patients With Advanced Myeloproliferative Neoplasms (MPNs) That Have an IDH1 Gene Mutation","status":"RECRUITING","sponsor":"University of Chicago","startDate":"2024-09-19","conditions":"Myeloproliferative Neoplasms","enrollment":18},{"nctId":"NCT03564821","phase":"PHASE1","title":"IDH1 Inhibition Using Ivosidenib as Maintenance Therapy for IDH1-mutant Myeloid Neoplasms Following Allogeneic Stem Cell Transplantation","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2019-01-16","conditions":"IDH1 Mutation Myeloid Neoplasms","enrollment":18},{"nctId":"NCT04278781","phase":"PHASE2","title":"AG-120 in People With IDH1 Mutant Chondrosarcoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2020-03-04","conditions":"Chondrosarcoma, Chondrosarcoma, Grade 2, Chondrosarcoma, Grade 3","enrollment":6},{"nctId":"NCT04777916","phase":"","title":"Prospective Non-interventional Study of Adult Patients With Acute Myeloid Leukemia (AML)","status":"RECRUITING","sponsor":"Acute Leukemia French Association","startDate":"2022-04-14","conditions":"Acute Myeloid Leukemia (AML)","enrollment":5000},{"nctId":"NCT05209074","phase":"PHASE1","title":"Ivosidenib + mFOLFIRINOX in Patients With Resectable Pancreatic Adenocarcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Case Comprehensive Cancer Center","startDate":"2022-09-08","conditions":"Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Cancer","enrollment":16},{"nctId":"NCT07131059","phase":"NA","title":"MRD-positive AML Clinical Study","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2024-05-11","conditions":"AML, Adult","enrollment":120},{"nctId":"NCT07075016","phase":"PHASE3","title":"Ivosidenib and Azacitidine With or Without Venetoclax in Adult Patients With Newly Diagnosed IDH1-Mutated AML or MDS/AML Considered Ineligible for Intensive Chemotherapy","status":"RECRUITING","sponsor":"Stichting Hemato-Oncologie voor Volwassenen Nederland","startDate":"2025-08-05","conditions":"Acute Myeloid Leukemia","enrollment":227},{"nctId":"NCT05030441","phase":"PHASE2","title":"Ivosidenib for Patients With Clonal Cytopenia of Undetermined Significance and Mutations in IDH1","status":"ACTIVE_NOT_RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2022-04-01","conditions":"Clonal Cytopenia of Undetermined Significance","enrollment":20},{"nctId":"NCT06265545","phase":"NA","title":"Multicenter, Platform-type Clinical Study of Refractory/Recurrent Acute Myeloid Leukemia","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2024-02-22","conditions":"AML, Refractory, Relapsed","enrollment":120},{"nctId":"NCT03680677","phase":"","title":"Frailty Phenotype Assessments to Optimize Treatment Strategies for Older Patients With Hematologic Malignancies","status":"RECRUITING","sponsor":"Abramson Cancer Center at Penn Medicine","startDate":"2018-09-21","conditions":"Leukemia, Acute, MDS","enrollment":20},{"nctId":"NCT06717958","phase":"PHASE2","title":"Prospective Evaluation of Ivosidenib Maintenance Following Allogeneic Stem Cell Transplantation in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Neoplasia With IDH1 (Isocitrate Dehydrogenase 1) Mutation","status":"RECRUITING","sponsor":"Technische Universität Dresden","startDate":"2025-06-17","conditions":"AML, MDS","enrollment":76},{"nctId":"NCT04603001","phase":"PHASE1","title":"Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2020-11-19","conditions":"Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Chronic Myelomonocytic Leukemia (CMML)","enrollment":260},{"nctId":"NCT02074839","phase":"PHASE1","title":"Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation","status":"RECRUITING","sponsor":"Institut de Recherches Internationales Servier","startDate":"2014-03-01","conditions":"Relapsed or Refractory Acute Myeloid Leukemia (AML), Untreated AML, Other IDH1-mutated Positive Hematologic Malignancies","enrollment":291},{"nctId":"NCT07007949","phase":"PHASE2","title":"a New Treatment of Newly Diagnosed IDH1 Mutation Acute Myeloid Leukemia","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2025-06-01","conditions":"Acute Myeloid Leukemia, IDH1 Gene Mutation, Ivosidenib","enrollment":42},{"nctId":"NCT03503409","phase":"PHASE2","title":"IDH1 (AG 120) Inhibitor in Patients With IDH1 Mutated Myelodysplastic Syndrome","status":"ACTIVE_NOT_RECRUITING","sponsor":"Groupe Francophone des Myelodysplasies","startDate":"2019-05-14","conditions":"Myelodysplastic Syndromes, Acute Myeloid Leukemia","enrollment":68},{"nctId":"NCT05401097","phase":"PHASE2","title":"IDH Targeted/Non- Targeted vs Non-targeted/IDH-targeted Approaches in the Treatment of Newly Diagnosed IDH Mutated AML Patients Not Candidates for Intensive Induction Therapy (I- DATA Study)","status":"RECRUITING","sponsor":"Alice Mims","startDate":"2022-09-13","conditions":"Acute Myeloid Leukemia","enrollment":125},{"nctId":"NCT05615818","phase":"PHASE3","title":"Personalized Medicine for Advanced Biliary Cancer Patients","status":"RECRUITING","sponsor":"UNICANCER","startDate":"2024-07-18","conditions":"Biliary Tract Neoplasms","enrollment":800},{"nctId":"NCT05907057","phase":"PHASE3","title":"An Open-label Phase 3b Study of Ivosidenib in Combination With Azacitidine in Adult Patients Newly Diagnosed With IDH1m Acute Myeloid Leukemia (AML) Ineligible for Intensive Induction Chemotherapy.","status":"RECRUITING","sponsor":"Servier Affaires Médicales","startDate":"2023-06-14","conditions":"Acute Myeloid Leukemia (AML)","enrollment":245},{"nctId":"NCT02632708","phase":"PHASE1","title":"Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and/or IDH2 Mutation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Institut de Recherches Internationales Servier","startDate":"2015-12-31","conditions":"Newly Diagnosed Acute Myeloid Leukemia (AML), Untreated AML, AML Arising From Myelodysplastic Syndrome (MDS)","enrollment":153},{"nctId":"NCT04056910","phase":"PHASE2","title":"Ivosidenib (AG-120) With Nivolumab in IDH1 Mutant Tumors","status":"COMPLETED","sponsor":"Jason J. Luke, MD","startDate":"2021-09-20","conditions":"Advanced Solid Tumor, IDH1 Mutation, Glioma","enrollment":15},{"nctId":"NCT04250051","phase":"PHASE1","title":"Ivosidenib and Combination Chemotherapy for the Treatment of IDH1 Mutant Relapsed or Refractory Acute Myeloid Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Northwestern University","startDate":"2020-12-21","conditions":"Recurrent Acute Myeloid Leukemia, Recurrent Myelodysplastic Syndrome, Recurrent Myeloproliferative Neoplasm","enrollment":2},{"nctId":"NCT03839771","phase":"PHASE3","title":"A Study of Ivosidenib or Enasidenib in Combination With Induction Therapy and Consolidation Therapy, Followed by Maintenance Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myedysplastic Syndrome EB2, With an IDH1 or IDH2 Mutation, Respectively, Eligible for Intensive Chemotherapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Stichting Hemato-Oncologie voor Volwassenen Nederland","startDate":"2019-03-01","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndrome With Excess Blasts-2","enrollment":968},{"nctId":"NCT06593548","phase":"PHASE2","title":"Lvosidenib (AK112) Combined With CapeOX and Radiotherapy in Patients With Unresectable Metastatic MSS-type Colorectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2024-11-01","conditions":"CRC, MSS, Metastatic Cancer","enrollment":36},{"nctId":"NCT02989857","phase":"PHASE3","title":"Study of AG-120 in Previously Treated Advanced Cholangiocarcinoma With IDH1 Mutations (ClarIDHy)","status":"COMPLETED","sponsor":"Institut de Recherches Internationales Servier","startDate":"2017-02-20","conditions":"Advanced Cholangiocarcinoma, Metastatic Cholangiocarcinoma","enrollment":187},{"nctId":"NCT04955938","phase":"PHASE1","title":"A Study of Fedratinib With IDH Inhibition in Advanced-Phase, IDH-Mutated Ph-Negative Myeloproliferative Neoplasms","status":"WITHDRAWN","sponsor":"University of Chicago","startDate":"2021-10-29","conditions":"IDH Mutation, IDH1 Mutation, IDH2 Gene Mutation","enrollment":""},{"nctId":"NCT04088188","phase":"PHASE1","title":"Gemcitabine and Cisplatin With Ivosidenib or Pemigatinib for the Treatment of Unresectable or Metastatic Cholangiocarcinoma","status":"TERMINATED","sponsor":"Academic and Community Cancer Research United","startDate":"2021-01-25","conditions":"Advanced Cholangiocarcinoma, Metastatic Cholangiocarcinoma, Unresectable Cholangiocarcinoma","enrollment":8},{"nctId":"NCT02665065","phase":"PHASE3","title":"Study of Iomab-B vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Actinium Pharmaceuticals","startDate":"2016-06","conditions":"Acute Myeloid Leukemia, Leukemia, Acute Myeloid, Myeloid Leukemia, Acute","enrollment":153},{"nctId":"NCT04176393","phase":"PHASE1","title":"A China Bridging Study of Ivosidenib in r/r AML Subjects With an IDH1 Mutation","status":"COMPLETED","sponsor":"CStone Pharmaceuticals","startDate":"2019-11-12","conditions":"Relapsed or Refractory Acute Myeloid Leukemia","enrollment":30},{"nctId":"NCT04655391","phase":"PHASE1","title":"Glasdegib-Based Treatment Combinations for the Treatment of Patients With Relapsed Acute Myeloid Leukemia Who Have Undergone Hematopoietic Cell Transplantation","status":"WITHDRAWN","sponsor":"City of Hope Medical Center","startDate":"2022-06-25","conditions":"Recurrent Acute Myeloid Leukemia","enrollment":""},{"nctId":"NCT04044209","phase":"PHASE2","title":"A Study of the IDH1 Inhibitor AG-120 in Combination With the Checkpoint Blockade Inhibitor, Nivolumab, for Patients With IDH1 Mutated Relapsed/Refractory AML and High Risk MDS","status":"WITHDRAWN","sponsor":"Yale University","startDate":"2020-02-12","conditions":"Myelodysplastic Syndromes, Acute Myeloid Leukemia","enrollment":""},{"nctId":"NCT03245424","phase":"","title":"Ivosidenib Expanded Access Program in Relapsed/Refractory AML With an IDH1 Mutation","status":"APPROVED_FOR_MARKETING","sponsor":"Agios Pharmaceuticals, Inc.","startDate":"","conditions":"Acute Myeloid Leukemia, Relapsed Adult AML, Relapsed Pediatric AML","enrollment":""},{"nctId":"NCT03282513","phase":"PHASE1","title":"A Study of AG-120 (Ivosidenib) in Subjects With Mild or Moderate Hepatic Impairment or Normal Hepatic Function","status":"COMPLETED","sponsor":"Agios Pharmaceuticals, Inc.","startDate":"2017-09-26","conditions":"Hepatic Impairment","enrollment":33},{"nctId":"NCT03071770","phase":"PHASE1","title":"Japanese Bridging Study of Ivosidenib (AG-120) in Healthy Subjects","status":"COMPLETED","sponsor":"Agios Pharmaceuticals, Inc.","startDate":"2017-03-31","conditions":"Healthy","enrollment":60},{"nctId":"NCT02831972","phase":"PHASE1","title":"Drug-Drug Interaction Study of AG120 in Healthy Subjects","status":"COMPLETED","sponsor":"Agios Pharmaceuticals, Inc.","startDate":"2016-06","conditions":"Healthy","enrollment":22},{"nctId":"NCT02579707","phase":"PHASE1","title":"Food Effect Study of AG120 in Healthy Subjects","status":"COMPLETED","sponsor":"Agios Pharmaceuticals, Inc.","startDate":"2015-10","conditions":"Healthy","enrollment":36},{"nctId":"NCT02489513","phase":"PHASE1","title":"Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-AG-120","status":"COMPLETED","sponsor":"Agios Pharmaceuticals, Inc.","startDate":"2015-06","conditions":"Healthy Volunteers","enrollment":8}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":52,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_1","status":"active","brandName":"AG120","genericName":"AG120","companyName":"Agios Pharmaceuticals, Inc.","companyId":"agios-pharmaceuticals-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Inhibits mutant IDH1 enzyme Used for Acute myeloid leukemia (AML) with isocitrate dehydrogenase 1 (IDH1) mutation.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}